Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

One has a top COVID-19 treatment, the other has a top COVID-19 vaccine. Which stock will come out on top.

Better Buy: Gilead Sciences vs. Pfizer

Gilead Sciences (NASDAQ: GILD) shares are advancing this January, and at the current stock price, this company is fairly valued, in my opinion. The company is moving in the right direction, and the positive news is that Morgan & Stanley upgraded its price target on Gilead Sciences.

Gilead Sciences shares rise as Morgan Stanley upgrades its price target to $83

Gilead has underperformed the S&P 500 in recent years, but that may be set to change as the company returns to growth with market valuations stretched. Gilead not only provides investors with a defensive business not heavily linked to the economic cycle, but also should provide inflation protection as hefty government deficits continue.

Gilead: Outperformance From Defense And Inflation Protection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 4, after the market closes. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's fourth quarter and full year 2020 financial results and will provide a business update. The live webcast of the call can be accessed at the company's Investors page at http://inves

Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021

Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.

Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?

Gilead stock rocketed Tuesday after an analyst suggested 2021 would be a pivotal year as it advances key medicines for HIV and breast cancer. Gilead stock hit its highest point since August.

Gilead's 'Pivotal Year' — Why An Analyst Is Bullish Enough To Upgrade Shares

Galapagos

Gilead Sciences, Inc. (NASDAQ: GILD) and its R&D partner Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) received an upgrade each from Morgan Stanley. The Gilead, Galapagos Analyst: Matthew Harrison upgraded Gilead from Equal-weight from Overweight and increased the price target from $67 to $83.

The Gilead, Galapagos Pipeline Opportunities That Are Turning Morgan Stanley Bullish

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr. Marincola will lead Kite's Research organization across hematological malignancies and solid tumors. “Franco's proven track record in oncology and robust research experience that spans the NIH to industry will be critical to the targeting and acceleration of o

Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research

Amgen

Eli Lilly

Merck

Merck and Amgen are major pharmaceuticals that experienced slowing sales in the mid 2010s due to patent expirations and biosimilar competition. However, Merck recently experienced strong bottom line growth due to their expanding oncology and vaccine divisions.

Dividend Growth Pharmaceuticals For 2021

Intel

QUALCOMM

Alaska's Department of Revenue dramatically raised its investment in Tesla stock, and reduced investments in Intel, Gilead Sciences, and Qualcomm shares in the fourth quarter.

Alaska Loaded Up on Tesla Stock. Here Are 3 Stocks It Sold.

Gilead Sciences isn't betting its 2021 on coronavirus treatment Veklury. But the biotech company still sees plenty of catalysts in oncology, virology and inflammation for Gilead stock.

Gilead Stock 2021: Why The Biotech Stock Isn't Depending On Covid Drugs

Gilead has vainly sailed the seas in search of growing biotech riches for the last five years. Gilead's VEKLURY (remdesivir) is gaining near-term traction to replenish Gilead's finances and its shareholders' confidence.

Gilead: The Widow's Walk

The biotech made headlines last year as the first to market a coronavirus treatment. What's in store for it in 2021?

Is Gilead Sciences a Good Coronavirus Stock to Buy?

Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.

Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand

Vir Biotechnology

FOSTER CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV). The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naïve people living with HBV. The mul

Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

Gilead Sciences, Inc. (GILD) Dan O'Day Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)

Mechelen, Belgium; 11 January 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc.

Gilead holds 25.54% of Galapagos shares

Daniel O'Day, the CEO of Gilead Sciences Inc. (NASDAQ: GILD), told CNBC on Monday that the drugmaker expects the antiviral drug to be fully effective against new strains of the coronavirus.  What Happened: O'Day appeared on CNBC's “Squawk Box.

Gilead CEO: We Expect Remdesivir To Work On New COVID-19 Strains

"I expect remdesivir with these variants will continue to make an impact on patients," Gilead Sciences CEO Daniel O'Day told CNBC.

Gilead CEO expects remdesivir to effectively treat Covid strains found in U.K., South Africa

Gilead Sciences Inc. updated its guidance for 2020 on Monday, raising its outlook for sales to reflect sales of COVID-19 treatment remdesivir, while narrowing and lowering the top end of its per-share outlook. In a statement released ahead of a presentation at J.P.

Gilead updates 2020 guidance to raise sales outlook, tighten and lower top end of EPS range

Gilead Sciences Inc raised its full-year profit forecast on Monday, boosted by increased sales of COVID-19 treatment remdesivir, as hospitalization and treatment rates were higher than expected given the most recent surge in cases.

Gilead raises 2020 profit forecast

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has revised certain elements of its full year 2020 guidance. Updated Full Year 2020 Guidance (In millions, except percentages and per share amounts) Previously Updated October 28, 2020 Updated January 11, 2021 Product Sales $23,000 - $23,500 $24,300 - $24,350 Product Sales excluding Veklury   $21,500 - $21,525 Veklury   $2,800 - $2,825 Non-GAAP     Product Gross Margin 86% - 87% ~ 86.5% R&

Gilead Sciences Announces Updated 2020 Guidance

argenx

EyePoint Pharmaceuticals

Gracell Biotechnologies

Inovio Pharmaceuticals

Paratek Pharma

Zai Lab Ltd.

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments.

Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs

AstraZeneca

AstraZeneca and Gilead Sciences should rebound nicely this year.

2 Top Value Stocks to Own in 2021

SANTA MONICA, Calif. & OXFORD, England & SAN JOSE, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. Through this collaboration, OBT will validate five novel onc

News for Gilead Sciences Stock (GILD)